Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure

Dermatomyositis (DM) is a chronic idiopathic inflammatory condition involving the skin and muscles that classically presents with a heliotrope rash and Gottron’s papules.1 Intravenous immune globulin is currently the only FDA-approved treatment for DM. Other treatments include photoprotection, topical corticosteroids, antimalarials, and traditional systemic immunosuppressants.1 Unfortunately, many patients are treatment refractory, highlighting the need for additional effective and safe therapies.